SCHEMBL1744725

SCHEMBL1744725

CC(C)CCN(Cc1ccc(COc2ccc(CCC(=O)O)cc2)cc1)c1nc(-c2ccccc2)cs1

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 9/20 0.55
PPARD Q03181 6/20 0.50
PPARG P37231 2/20 0.49
FFAR4 Q5NUL3 3/20 0.47
KMT2A Q03164 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 2/20 0.46
PPARA Q07869 1/20 0.46
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
AKR1B1 P15121 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745532 0.93 FFAR1 (0.55) FFAR1PPARDFFAR4KMT2ANPSR1
SCHEMBL1744677 0.93 FFAR1 (0.47) FFAR1PPARDPPARGKMT2ANPSR1
SCHEMBL3912223 0.91 PPARD (0.57) FFAR1PPARDPPARGFFAR4KMT2A
SCHEMBL1745053 0.90 FFAR1 (0.53) FFAR1PPARDPPARGFFAR4KMT2A
SCHEMBL3921961 0.90 PPARD (0.54) FFAR1PPARDPPARGFFAR4KMT2A
SCHEMBL3917969 0.90 PPARD (0.53) FFAR1PPARDPPARGFFAR4PPARA
SCHEMBL3914638 0.89 FFAR1 (0.58) FFAR1PPARDFFAR4KMT2ANPSR1
SCHEMBL3911382 0.89 PPARD (0.58) FFAR1PPARDPPARGFFAR4KMT2A
SCHEMBL1746802 0.88 FFAR1 (0.55) FFAR1PPARDFFAR4KMT2ANPSR1
SCHEMBL3921211 0.88 KMT2A (0.58) FFAR1PPARDPPARGFFAR4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885PPARD 326/4885PPARG 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.